Last updated on January 2010

Advanced Ovarian Cancer

Brief description of study

Advanced Ovarian Cancer

Detailed Study Description

To investigate the efficacy and safety of BIBF 1120 plus chemotherapy as compared to placebo plus chemotherapy in patients with advanced ovarian cancer

Patient Inclusion Criteria:

  • Patients with histologically proven epithelial ovarian cancer, fallopian tube or primary peritoneal cancer of advanced stage, 18 + years of age, life expectancy of at least 6 months

Patient Exclusion Criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum, clinically relevant non-healing would, ulcer or bone fracture, clinical symptoms of brain metastases

Clinical Study Identifier: TX134751

Contact Investigators or Research Sites near you

Start Over

Dr. Tom Davis

Legacy Pharma Research
Bismarck, ND USA
  Connect »